|Videos|October 25, 2016

Immunotherapy: An Alternative to Antibiotics?

Marcos Pires, PhD, assistant professor at Lehigh University, explains the main points behind his research regarding immunotherapy.

Marcos Pires, PhD, assistant professor at Lehigh University, explains the main points behind his research regarding immunotherapy.

Interview Transcript (slightly modified for readability)

“In our research at Lehigh University, we’re working towards making molecules that decorate the surface of the bacterial cells, and they decorate them in a very special way in that they’re being decorated with antigens and the antigens are molecules that recruit antibodies. The idea is that if we’re able to make molecules that go and tag the surface of pathogenic bacteria, and in those tags if we have a way to then attract antibodies, then bacteria should be tagged with antibodies for destruction. At that point, the body has enough information to actually come in and detect bacteria that have been tagged and then go on to actually remove them from the system. That’s the main part of our research: thinking about molecules and designing molecules that are able to operate in this manner.”


Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.